Joel Greenblatt’s Intra-Cellular Therapies Inc. ITCI Stock Holding History

Joel Greenblatt’s Portfolio ITCI Stock Details ITCI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q2	–	Sell	-18,508	Closed	-$2.44M	–	1764
2025 Q1	$2.44M	Buy	18,508 +7,501	+68%	+$935K	0.02%	735
2024 Q4	$919K	Buy	11,007 +1,501	+16%	+$123K	0.01%	947
2024 Q3	$696K	Buy	9,506 +4,220	+80%	+$317K	0.01%	1010
2024 Q2	$362K	Buy	+5,286	New	+$367K	﹤0.01%	1177
2017 Q1	–	Sell	-17,079	Closed	-$258K	–	1124
2016 Q4	$258K	Buy	+17,079	New	+$241K	﹤0.01%	839

Other funds holding ITCI

DekaBank Deutsche Girozentrale Frankfurt, Germany $59.2B AUM 26.02% 1-Year Est. Return

Osaic Holdings Scottsdale, Arizona $85.1B AUM 27.35% 1-Year Est. Return

KIM

Kestra Investment Management Austin, Texas $5.16B AUM 18.64% 1-Year Est. Return

HNB

Huntington National Bank Columbus, Ohio $20.6B AUM 34.61% 1-Year Est. Return

Joel Greenblatt's ITCI Position: Q2 2025 in Review

Joel Greenblatt sold out of Intra-Cellular Therapies Inc. (ITCI) in Q2 2025, closing a stake of 18,508 shares — an estimated $2.44M sold.

Joel Greenblatt first reported a position in ITCI in Q4 2016 and held it in 5 quarters. The position peaked at $2.44M in Q1 2025. 4 funds tracked by Wall St. Rank hold ITCI as of Q2 2025.

Joel Greenblatt reported no remaining Intra-Cellular Therapies Inc. position as of Q2 2025 after selling out during the quarter.
Joel Greenblatt sold 18,508 Intra-Cellular Therapies Inc. shares in Q2 2025, an estimated $2.44M.
Joel Greenblatt first reported a position in Intra-Cellular Therapies Inc. in Q4 2016 and held it in 5 quarters.
Joel Greenblatt's Intra-Cellular Therapies Inc. position peaked at $2.44M in Q1 2025.
4 funds tracked by Wall St. Rank held Intra-Cellular Therapies Inc. as of Q2 2025.

Based on Gotham Asset Management's 13F filing for Q2 2025, filed 14 Aug 2025.